Roswell Biotechnologies announced an early drug discovery research collaboration with global biopharmaceutical company UCB. Under the collaboration, UCB will work with Roswell to evaluate the Roswell Molecular Electronics Platform (Roswell ME Platform) and Roswell Molecular Electronics Chip™ (Roswell ME Chip) for use in drug discovery for neurological, immunological, and rare diseases. Roswell unveiled the Roswell ME Chip in November 2021 with a roadmap that includes early collaborations across industries, followed by an open access program, and full commercial launch.

This collaboration marks the first of a number of upcoming early collaborations to advance toward commercialization.